Literature DB >> 28572092

Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor.

Virginia Sanchez-Quiles1, Vyacheslav Akimov1, Nerea Osinalde1, Chiara Francavilla2, Michele Puglia1, Inigo Barrio-Hernandez1, Irina Kratchmarova1, Jesper V Olsen2, Blagoy Blagoev3.   

Abstract

Cylindromatosis tumor suppressor protein (CYLD) is a deubiquitinase, best known as an essential negative regulator of the NFkB pathway. Previous studies have suggested an involvement of CYLD in epidermal growth factor (EGF)-dependent signal transduction as well, as it was found enriched within the tyrosine-phosphorylated complexes in cells stimulated with the growth factor. EGF receptor (EGFR) signaling participates in central cellular processes and its tight regulation, partly through ubiquitination cascades, is decisive for a balanced cellular homeostasis. Here, using a combination of mass spectrometry-based quantitative proteomic approaches with biochemical and immunofluorescence strategies, we demonstrate the involvement of CYLD in the regulation of the ubiquitination events triggered by EGF. Our data show that CYLD regulates the magnitude of ubiquitination of several major effectors of the EGFR pathway by assisting the recruitment of the ubiquitin ligase Cbl-b to the activated EGFR complex. Notably, CYLD facilitates the interaction of EGFR with Cbl-b through its Tyr15 phosphorylation in response to EGF, which leads to fine-tuning of the receptor's ubiquitination and subsequent degradation. This represents a previously uncharacterized strategy exerted by this deubiquitinase and tumors suppressor for the negative regulation of a tumorigenic signaling pathway.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28572092      PMCID: PMC5546196          DOI: 10.1074/mcp.M116.066423

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  64 in total

Review 1.  Reading protein modifications with interaction domains.

Authors:  Bruce T Seet; Ivan Dikic; Ming-Ming Zhou; Tony Pawson
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

2.  Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics.

Authors:  Philipp Mertins; H Christian Eberl; Jörg Renkawitz; Jesper V Olsen; Michel L Tremblay; Matthias Mann; Axel Ullrich; Henrik Daub
Journal:  Mol Cell Proteomics       Date:  2008-05-31       Impact factor: 5.911

3.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

Review 4.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

5.  Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation.

Authors:  C Elly; S Witte; Z Zhang; O Rosnet; S Lipkowitz; A Altman; Y C Liu
Journal:  Oncogene       Date:  1999-02-04       Impact factor: 9.867

6.  Induction of membrane circular dorsal ruffles requires co-signalling of integrin-ILK-complex and EGF receptor.

Authors:  S Babak Azimifar; Ralph T Böttcher; Sara Zanivan; Carsten Grashoff; Marcus Krüger; Kyle R Legate; Matthias Mann; Reinhard Fässler
Journal:  J Cell Sci       Date:  2012-01-15       Impact factor: 5.285

7.  The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.

Authors:  Andrew Kovalenko; Christine Chable-Bessia; Giuseppina Cantarella; Alain Israël; David Wallach; Gilles Courtois
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

8.  Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.

Authors:  Gareth C Davies; Seth A Ettenberg; Ashley O Coats; Mark Mussante; Sarangan Ravichandran; Jack Collins; Marion M Nau; Stan Lipkowitz
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

9.  A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation.

Authors:  Steven Pennock; Zhixiang Wang
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

10.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  5 in total

Review 1.  CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.

Authors:  Zhibin Cui; Hyunseok Kang; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Res       Date:  2020-09-03       Impact factor: 6.333

2.  Data on mass spectrometry-based proteomics for studying the involvement of CYLD in the ubiquitination events downstream of EGFR activation.

Authors:  Virginia Sanchez-Quiles; Nerea Osinalde; Vyacheslav Akimov; Irina Kratchmarova; Blagoy Blagoev
Journal:  Data Brief       Date:  2018-04-25

3.  The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Rin Liu; Satoru Shinriki; Manabu Maeshiro; Mayumi Hirayama; Hirofumi Jono; Ryoji Yoshida; Hideki Nakayama; Hirotaka Matsui
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

4.  Adipose MDM2 regulates systemic insulin sensitivity.

Authors:  Philip Hallenborg; Benjamin Anderschou Holbech Jensen; Even Fjære; Rasmus Koefoed Petersen; Mohammed-Samir Belmaâti; Sarah Søndergård Rasmussen; Jon Petur Gunnarsson; Pernille Lauritzen; Kenneth King Yip Cheng; Martin Hermansson; Si Brask Sonne; Christer S Ejsing; Aimin Xu; Irina Kratchmarova; Marcus Krüger; Lise Madsen; Karsten Kristiansen; Blagoy Blagoev
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

5.  Phosphoproteomic profiling reveals a defined genetic program for osteoblastic lineage commitment of human bone marrow-derived stromal stem cells.

Authors:  Inigo Barrio-Hernandez; Abbas Jafari; Kristoffer T G Rigbolt; Philip Hallenborg; Virginia Sanchez-Quiles; Ida Skovrind; Vyacheslav Akimov; Irina Kratchmarova; Joern Dengjel; Moustapha Kassem; Blagoy Blagoev
Journal:  Genome Res       Date:  2019-12-12       Impact factor: 9.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.